|
Oncogenes and Tumor Suppressors
Citations 311-320 of 795 total displayed.
|
Past content
(since May 2000):
|
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia
- Jaroslav Jelinek, Yasuhiro Oki, Vazganush Gharibyan, Carlos Bueso-Ramos, Josef T. Prchal, Srdan Verstovsek, Miloslav Beran, Elihu Estey, Hagop M. Kantarjian, and Jean-Pierre J. Issa
Blood 2005; 106: 3370-3373.
[Abstract]
[Full text]
[PDF]
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
- Robert Kralovics, Soon-Siong Teo, Andreas S. Buser, Martin Brutsche, Ralph Tiedt, Andre Tichelli, Francesco Passamonti, Daniela Pietra, Mario Cazzola, and Radek C. Skoda
Blood 2005; 106: 3374-3376.
[Abstract]
[Full text]
[PDF]
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
- Ross L. Levine, Marc Loriaux, Brian J. P. Huntly, Mignon L. Loh, Miroslav Beran, Eric Stoffregen, Roland Berger, Jennifer J. Clark, Stephanie G. Willis, Kim T. Nguyen, Nikki J. Flores, Elihu Estey, Norbert Gattermann, Scott Armstrong, A. Thomas Look, James D. Griffin, Olivier A. Bernard, Michael C. Heinrich, D. Gary Gilliland, Brian Druker, and Michael W. N. Deininger
Blood 2005; 106: 3377-3379.
[Abstract]
[Full text]
[PDF]
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
- Bianca F. Goemans, Christian M. Zwaan, Amy Harlow, Anne H. Loonen, Brenda E. S. Gibson, Karel Hählen, Dirk Reinhardt, Ursula Creutzig, Michael C. Heinrich, and Gertjan J. L. Kaspers
Blood 2005; 106: 3532-3537.
[Abstract]
[Full text]
[PDF]
A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus
- Sys Zoffmann Glud, Annette Balle Sørensen, Mindaugas Andrulis, Bruce Wang, Eisaku Kondo, Randi Jessen, Laszlo Krenacs, Eva Stelkovics, Matthias Wabl, Edgar Serfling, Alois Palmetshofer, and Finn Skou Pedersen
Blood 2005; 106: 3546-3552.
[Abstract]
[Full text]
[PDF]
Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells
- Maria Thomas, Andreas Geßner, Hans-Peter Vornlocher, Philipp Hadwiger, Johann Greil, and Olaf Heidenreich
Blood 2005; 106: 3559-3566.
[Abstract]
[Full text]
[PDF]
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
- Thorsten Stühmer, Manik Chatterjee, Martin Hildebrandt, Pia Herrmann, Hella Gollasch, Christian Gerecke, Sebastian Theurich, Luisa Cigliano, Rudolf A. Manz, Peter T. Daniel, Kurt Bommert, Lyubomir T. Vassilev, and Ralf C. Bargou
Blood 2005; 106: 3609-3617.
[Abstract]
[Full text]
[PDF]
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
- Nicolas Boissel, Aline Renneville, Valeria Biggio, Nathalie Philippe, Xavier Thomas, Jean-Michel Cayuela, Christine Terre, Isabelle Tigaud, Sylvie Castaigne, Emmanuel Raffoux, Stephane De Botton, Pierre Fenaux, Herve Dombret, and Claude Preudhomme, for the Acute Leukemia French Association (ALFA)
Blood 2005; 106: 3618-3620.
[Abstract]
[Full text]
[PDF]
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma
- Mondira Kundu, Sheila Compton, Lisa Garrett-Beal, Terryl Stacy, Matthew F. Starost, Michael Eckhaus, Nancy A. Speck, and P. Paul Liu
Blood 2005; 106: 3621-3624.
[Abstract]
[Full text]
[PDF]
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
- Rosemary E. Gale, Robert Hills, Panagiotis D. Kottaridis, Sivatharsini Srirangan, Keith Wheatley, Alan K. Burnett, and David C. Linch
Blood 2005; 106: 3658-3665.
[Abstract]
[Full text]
[PDF]
|
|
